- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASH 2023: PERSEUS Trial Overview
Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The PERSEUS trial compared bortezomib, lenalidomide, and dexamethasone (VRd) to lenalidomide, bortezomib, and dexamethasone plus daratumumab (D-VRd) in over 700 newly diagnosed, transplant-eligible multiple myeloma patients. After induction, stem cell transplant, and consolidation with the same regimens, patients in the VRd arm received lenalidomide maintenance while patients in the D-VRd armreceived daratumumab plus lenalidomide. Importantly, minimal residual disease (MRD) testing occurred, allowing therapy discontinuation in sustained MRD-negative complete responders after 2 years.
At 4 years, progression-free survival was 84.3% with D-VRd vs 67.7% with VRd (HR, 0.42), a statistically significant difference. Response rates including complete response and MRD negativity also favored D-VRd. Given the strength of these phase 3 results, D-VRd should be considered for initial induction for transplant-eligible myeloma. Adding daratumumab improves outcomes, including in the maintenance setting, while generic availability makes this affordable globally.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
